CEPI, the Coalition for Epidemic Preparedness Innovations, has signed a ninth worldwide collaboration to develop a COVID-19 vaccine. CEPI will invest an initial $3.5 million in a partnering agreement with Clover Biopharmaceuticals Australia, the wholly-owned subsidiary of Sichuan Clover Biopharmaceuticals, Inc. (China). The deal brings the organization’s total investment in COVID-19 vaccine research and development to $39.6 million.
 
This initial CEPI investment will support Clover Australia in its efforts to initiate a phase 1 clinical trial in Australia of its COVID-19 S-Trimer vaccine candidate. This innovative vaccine candidate is based on Clover Biopharmaceutical’s proprietary Trimer-Tag vaccine technology platform, which is a novel way to produce the spike proteins of the COVID-19 virus in a native trimeric form for use in a vaccine. If successful in clinical trials, Clover Biopharmaceuticals has the capacity to rapidly scale up the production of the vaccine using its in-house biomanufacturing capabilities.
 
“We are delighted to partner with Clover Australia on their innovative COVID-19 S-Trimer vaccine candidate,” said Richard Hatchett, chief executive officer, CEPI. “They produced their vaccine within a month of the virus sequence becoming available, and they have rapidly advanced toward a first in human trial. This vaccine candidate is an important new addition to the CEPI portfolio. CEPI has invested in a diverse range of innovative vaccine platforms, as well as more established vaccine technologies, to maximise our chances of success as we pursue our ambition of making COVID-19 vaccines available for broad use.”
 
Joshua Liang, chief strategy officer, Clover Biopharmaceuticals and co-inventor of COVID-19 S-Trimer vaccine candidate said, “At Clover Biopharmaceuticals, we are proud to receive CEPI’s funding and support for Clover Australia, which are critical to enabling the ongoing development and acceleration of our COVID-19 S-Trimer vaccine program that utilizes our innovative Trimer-Tag platform technology. We have been working tirelessly and hope to contribute significantly to global efforts in fighting this pandemic that has affected us all.”
 
To date, CEPI has provided initial support and funding to Curevac, Inc., Inovio Pharmaceuticals, Inc., Moderna, Inc., Novavax, Inc., The University of Hong Kong, The University of Oxford, The University of Queensland and a consortium led by Institut Pasteur to develop COVID-19 vaccine candidates.
 
This investment is the result of a recent global call for proposals that CEPI issued in early February, which invited funding applications for vaccine technology that could be used to rapidly develop a vaccine against the new coronavirus, and most importantly at scale and with the necessary equitable access provisions.
 
CEPI recently officially announced that it has opened a representative office in Shanghai. Through its Shanghai Representative OfficeCEPI will seek cooperation with China in the prevention and control of pandemic diseases, including funding of public health research projects, technical research and development of vaccines, and international scientific, technology and development cooperation and exchanges.